svlsf iv llc  insider monkey companies  see all hedge funds  see all insiders  see all institutional investors  see all click here to see all results for sorry no results has been found matching your query adblocker detected dear valued visitor we have noticed that you are using an ad blocker software although advertisements on the web pages may degrade your experience our business certainly depends on them and we can only keep providing you highquality research based articles as long as we can display ads on our pages to view this article you can disable your ad blocker and refresh this page or simply login we only allow registered users to use ad blockers you can sign up for free by clicking here or you can login if you are already a member home  insider trading  svlsf iv llc  profile svlsf iv llc profile insider purchases insider sales news affiliations large shareholder at entellus medical inc entl  large shareholder at kalvista pharmaceuticals inc kalv  large shareholder at ocular therapeutix inc ocul  large shareholder at ophthotech corp opht  large shareholder at transenterix inc trxc  large shareholder at neurogesx inc ngsx  insider trading purchases see all company symbol price amount relationship remaning holdings date form  entellus medical inc entl   large shareholder   filing entellus medical inc entl   large shareholder   filing ocular therapeutix inc ocul   large shareholder   filing ocular therapeutix inc ocul   large shareholder   filing ocular therapeutix inc ocul   large shareholder   filing insider trading sales see all company symbol price amount relationship remaining holdings date form  entellus medical inc entl   large shareholder   filing entellus medical inc entl   large shareholder   filing entellus medical inc entl   large shareholder   filing entellus medical inc entl   large shareholder   filing entellus medical inc entl   large shareholder   filing home hedge funds markets blog authors about us contact us privacy policy terms of use site map all text and design is copyright  koala guide llc all rights reserved safestitch medical inc  amended statement of beneficial ownership print email pdf word xls transenterix inc form sc ga received       united states securities and exchange commission washington dc      schedule ga under the securities exchange act of  amendment no      transenterix inc name of issuer common stock par value  per share title of class of securities m cusip number december   date of event which requires filing of this statement     check the appropriate box to designate the rule pursuant to which this schedule is filed ¨ rule db x rule dc ¨ rule dd    the remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page the information required in the remainder of this cover page shall not be deemed to be filed for the purpose of section  of the securities exchange act of  act or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act however see the notes       schedule g   cusip no m           names of reporting persons   svlsf iv llc      check the appropriate box if a member of a group see instructions a   ¨         b   ¨        sec use only        citizenship or place of organization   delaware number of shares beneficially owned by each reporting person with         sole voting power           shared voting power           sole dispositive power           shared dispositive power         aggregate amount beneficially owned by each reporting person       check if the aggregate amount in row  excludes certain shares see instructions      percent of class represented by amount in row         type of reporting person see instructions         based on  shares outstanding as of november      schedule g   cusip no m           names of reporting persons   sv life sciences fund iv lp      check the appropriate box if a member of a group see instructions a   ¨         b   ¨        sec use only        citizenship or place of organization   delaware number of shares beneficially owned by each reporting person with         sole voting power           shared voting power           sole dispositive power           shared dispositive power         aggregate amount beneficially owned by each reporting person       check if the aggregate amount in row  excludes certain shares see instructions      percent of class represented by amount in row         type of reporting person see instructions   pn      based on  shares outstanding as of november      schedule g   cusip no m           names of reporting persons   sv life sciences fund iv strategic partners lp      check the appropriate box if a member of a group see instructions a   ¨         b   ¨        sec use only        citizenship or place of organization   delaware number of shares beneficially owned by each reporting person with         sole voting power           shared voting power           sole dispositive power           shared dispositive power         aggregate amount beneficially owned by each reporting person       check if the aggregate amount in row  excludes certain shares see instructions      percent of class represented by amount in row         type of reporting person see instructions   pn      based on  shares outstanding as of november        schedule g   cusip no m           names of reporting persons   sv life sciences fund iv gp lp      check the appropriate box if a member of a group see instructions a   ¨         b   ¨        sec use only        citizenship or place of organization   delaware number of shares beneficially owned by each reporting person with         sole voting power           shared voting power           sole dispositive power           shared dispositive power         aggregate amount beneficially owned by each reporting person       check if the aggregate amount in row  excludes certain shares see instructions      percent of class represented by amount in row         type of reporting person see instructions   pn      based on  shares outstanding as of november      i tem      a name of issuer transenterix inc     b address of issuers principal executive offices  davis drive suite  morrisville north carolina  item      a name of person filing this statement is filed by i sv life sciences fund iv lp svls iv lp and sv life sciences fund iv strategic partners lp strategic partners each a delaware limited partnership direct owners of the shares of common stock of the issuer the shares ii sv life sciences fund iv gp lp a delaware limited partnership svls iv gp and general partner of svls iv lp and strategic partners and iii svlsf iv llc a delaware limited liability company and general partner of svls iv gp each of svls iv lp strategic partners svls iv gp and svlsf iv llc are sometimes individually referred to herein as a reporting person and collectively as the reporting persons     b address of the principal office or if none residence        the principal business address of the reporting persons is co sv life sciences one boston place  washington street suite  boston ma      c citizenship        each of the reporting persons are organized under the laws of the state of delaware     d title of class of securities        common stock par value  per share     e cusip number        m item  not applicable item  ownership provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in item      a amount beneficially owned the reporting persons may each be deemed to beneficially own in the aggregate  shares of common stock constituting approximately  of the common stock outstanding    as of the close of business on december   svls iv lp owned directly  shares of common stock constituting approximately  of the common stock outstanding as of the close of business on december   strategic partners owned directly  shares of common stock constituting approximately  of the common stock outstanding svls iv lp and strategic partners each a fund or collectively the funds may be deemed to beneficially own the shares held by each other fund because of certain contractual relationships among the funds and their affiliates the funds disclaim beneficial ownership of shares held by any other fund except to the extent of any pecuniary interest therein svls iv gp the general partner of svls iv lp and strategic partners may be deemed to share voting and dispositive power over the shares held by svls iv lp and strategic partners svls iv gp disclaims beneficial ownership of shares held by svls iv lp and strategic partners except to the extent of any pecuniary interest therein svlsf iv llc the general partner of svls iv gp may be deemed to share voting and dispositive power over the shares held by svls iv lp and strategic partners svlsf iv llc disclaims beneficial ownership of shares held by svls iv lp and strategic partners except to the extent of any pecuniary interest therein     b percent of class the reporting persons may each be deemed to beneficially own in the aggregate  based upon  shares of common stock outstanding as of november   item a is incorporated herein by reference     c number of shares as to which the person has     i sole power to vote or to direct the vote       ii shared power to vote or to direct the vote      iii sole power to dispose or to direct the disposition of       iv shared power to dispose or to direct the disposition of  instruction  for computations regarding securities which represent a right to acquire an underlying security see §dd item  ownership of five percent or less of a class not applicable    each of svls iv lp and strategic partners have sole power to vote and dispose of the shares they own directly each of strategic partners svls iv gp and svlsf iv llc may be deemed to have sole power to vote and dispose of the shares reported in this schedule g owned directly by svls iv lp each of svls iv lp svls iv gp and svlsf iv llc may be deemed to have sole power to vote and dispose of the shares reported in this schedule g owned directly by strategic partners    item  ownership of more than five percent on behalf of another person not applicable item  identification and classification of the subsidiary which acquired the security being reported on by the parent holding company not applicable item  identification and classification of members of the group see exhibit a attached hereto item  notice of dissolution of group not applicable item  certification by signing below i certify that to the best of my knowledge and belief the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under §a    after reasonable inquiry and to the best of my knowledge and belief i certify that the information set forth in this statement is true complete and correct dated february       svlsf iv llc by   s denise w marks name   denise marks title   member   sv life sciences fund iv gp lp by svlsf iv llc its general partner by   s denise w marks name   denise marks title   member   sv life sciences fund iv lp by sv life sciences fund iv gp lp its general partner by svlsf iv llc its general partner by   s denise w marks name   denise marks title   member   sv life sciences fund iv strategic partners lp by sv life sciences fund iv gp lp its general partner by svlsf iv llc its general partner by   s denise w marks name   denise marks title   member      exhibit index   exhibit a    joint filing agreement by and among sv life sciences fund iv lp sv life sciences fund iv strategic partners lp sv life sciences fund iv gp lp and svlsf iv llc dated december      filed herewith    exhibit a joint filing agreement in accordance with rule aj and rule dk and under the securities exchange act of  as amended the undersigned agree to the joint filing on behalf of each of them of forms    and schedules d and g including any and all amendments thereto with respect to the common stock par value  per share of transenterix inc and further agree that this joint filing agreement shall be included as an exhibit to such joint filings the undersigned further agree that each party hereto is responsible for the timely filing of such forms    and schedules d and lg and any amendments thereto and for the completeness and accuracy of the information concerning such party contained therein provided that no party is responsible for the completeness or accuracy of the information concerning any other filing party unless such party knows or has reason to believe that such information is inaccurate this joint filing agreement may be executed in one or more counterparts each of which shall be deemed to be an original instrument but all of such counterparts together shall constitute one agreement in evidence thereof the undersigned being duly authorized hereby execute this joint filing agreement as of december       svlsf iv llc by   s denise marks name   denise marks title   member   sv life sciences fund iv gp lp by svlsf iv llc its general partner by   s denise marks name   denise marks title   member   sv life sciences fund iv lp by sv life sciences fund iv gp lp its general partner by svlsf iv llc its general partner by   s denise marks name   denise marks title   member   sv life sciences fund iv strategic partners lp by sv life sciences fund iv gp lp its general partner by svlsf iv llc its general partner by   s denise marks name   denise marks title   member      bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version svlsf iv llc insider insider trades  nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search home  quotes  ownership  insider trades  individual insiders insider trades of svlsf iv llc click on the column header to resort ascending ▲ or descending ▼ individual insider trades company relation last date ▼ type tran ownertype shares traded last price shares held entellus medical inc beneficial owner   form  sell indirect    kalvista pharmaceuticals inc beneficial owner   form  acquisition non open market direct    highest rated articles of last week shareholders approve major structural change to top performing yatra attains leadership position in corporate travel with the mitel to acquire shoretel  quick facts miller heiman group selects calliduscloud datahug for pipeline tractor supply company reports second quarter results view all highest rated most rated stocks of last week rated stocks for nasdaq nyse and amex symbol  ratings consensus aapl  bullish of  ratings rate it fb  bullish of  ratings rate it tsla  bullish of  ratings rate it msft  bullish of  ratings rate it goog  bullish of  ratings rate it jpm  bullish of  ratings rate it gm  bullish of  ratings rate it bac  bullish of  ratings rate it nflx  bullish of  ratings rate it intc  bullish of  ratings rate it more most rated stocks closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex kalvista pharmaceuticals inc form sc d received       securities and exchange commission washington dc      schedule d under the securities exchange act of  amendment no          kalvista pharmaceuticals inc name of issuer common stock par value  per share title of class of securities  cusip number denise marks svlsf iv llc one boston place  washington street suite  boston ma    name address and telephone number of person authorized to receive notices and communications november   date of event which requires filing of this statement     if the filing person has previously filed a statement on schedule g to report the acquisition that is the subject of this schedule d and is filing this schedule because of §§ de df or dg check the following box   ☐     note schedules filed in paper format shall include a signed original and five copies of the schedule including all exhibits see § d for other parties to whom copies are to be sent        the remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page the information required on the remainder of this cover page shall not be deemed to be filed for the purpose of section  of the securities exchange act of  act or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act however see the notes        cusip no            name of reporting person   svlsf iv llc      check the appropriate box if a member of a group a  ☐        b  ☐        sec use only        source of funds   oo      check box if disclosure of legal proceedings is required pursuant to item d or e    ☐        citizenship or place of organization   delaware number of shares beneficially owned by each reporting person with             sole voting power             shared voting power               sole dispositive power           shared dispositive power         aggregate amount beneficially owned by each reporting person       check box if the aggregate amount in row  excludes certain shares    ☐      percent of class represented by amount in row         type of reporting person   oo    percentage calculated using a denominator of  shares of common stock of issuer as of december      cusip no            name of reporting person   sv life sciences fund iv lp      check the appropriate box if a member of a group a  ☐        b  ☐        sec use only        source of funds   oo      check box if disclosure of legal proceedings is required pursuant to item d or e    ☐        citizenship or place of organization   delaware number of shares beneficially owned by each reporting person with             sole voting power             shared voting power               sole dispositive power           shared dispositive power         aggregate amount beneficially owned by each reporting person       check box if the aggregate amount in row  excludes certain shares    ☐      percent of class represented by amount in row         type of reporting person   pn      cusip no            name of reporting person   sv life sciences fund iv strategic partners lp      check the appropriate box if a member of a group a  ☐        b  ☐        sec use only        source of funds   oo      check box if disclosure of legal proceedings is required pursuant to item d or e    ☐        citizenship or place of organization   delaware number of shares beneficially owned by each reporting person with             sole voting power             shared voting power               sole dispositive power           shared dispositive power         aggregate amount beneficially owned by each reporting person       check box if the aggregate amount in row  excludes certain shares    ☐      percent of class represented by amount in row         type of reporting person   pn      cusip no            name of reporting person   sv life sciences fund iv gp lp      check the appropriate box if a member of a group a  ☐        b  ☐        sec use only        source of funds   oo      check box if disclosure of legal proceedings is required pursuant to item d or e    ☐        citizenship or place of organization   delaware number of shares beneficially owned by each reporting person with             sole voting power             shared voting power               sole dispositive power           shared dispositive power         aggregate amount beneficially owned by each reporting person        check box if the aggregate amount in row  excludes certain shares    ☐      percent of class represented by amount in row         type of reporting person   pn      cusip no    the following constitutes the schedule d filed by the undersigned the schedule d   item  security and issuer this statement relates to the common stock par value  per share the common stock of kalvista pharmaceuticals inc the issuer the address of the principal executive offices of the issuer is one kendall square bld  ste  cambridge ma    item  identity and background a this statement is filed by i sv life sciences fund iv lp a delaware limited partnership svls iv lp and sv life sciences fund iv strategic partners lp a delaware limited partnership strategic partners and together with svls iv lp the funds each direct owners of the shares of common stock of the issuer together the shares ii sv life sciences fund iv gp lp a delaware limited partnership svls iv gp and general partner of svls iv lp and strategic partners and iii svlsf iv llc a delaware limited liability company and general partner of svls iv gp each of svls iv lp strategic partners svls iv gp and svlsf iv llc are sometimes individually referred to herein as a reporting person and collectively as the reporting persons b the principal business address of the reporting persons is co sv life sciences one boston place  washington street suite  boston ma  the principal business address of any person or entity listed on schedule a annexed hereto is set forth on schedule a annexed hereto c the principal business of the reporting persons is international life sciences venture capital investments svls iv lp and strategic partners are private venture capital funds svls iv gp is the general partner of svls iv lp and strategic partners svlsf iv llc is the general partner of svls iv gp the principal business of the persons or entities listed on schedule a annexed hereto is listed on schedule a annexed hereto d no reporting person nor any person or entity listed on schedule a annexed hereto has during the last five years been convicted in a criminal proceeding excluding traffic violations or similar misdemeanors e no reporting person nor any person or entity listed on schedule a annexed hereto has during the last five years been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment decree or final order enjoining future violations of or prohibiting or mandating activities subject to federal or state securities laws or finding any violation with respect to such laws f each of the individuals listed on schedule a annexed hereto are citizens of the country set forth on schedule a annexed hereto each of the reporting persons are organized under the laws of the state of delaware   item  source and amount of funds or other consideration the  shares of common stock owned directly by svls iv lp were acquired on november   in exchange for  shares of kalvista pharmaceuticals ltd series a preferred shares and  shares of kalvista pharmaceuticals ltd series b preferred shares in connection with the closing of the share purchase transaction the transaction whereby kalvista pharmaceuticals ltd became a whollyowned subsidiary of carbylan therapeutics inc which changed its name to kalvista pharmaceuticals inc the issuer    cusip no    the  shares of common stock owned directly by strategic partners were acquired on november   in exchange for  shares of kalvista pharmaceuticals ltd series a preferred shares and  shares of kalvista pharmaceuticals ltd series b preferred shares in connection with the closing of the transaction on the effective date of the transaction the closing price of the issuers common stock was  per share all numbers give effect to the  reverse stock split effected by the issuer on november   the reverse stock split prior to the reverse stock split the closing price of the issuers common stock was  per share   item  purpose of transaction the reporting persons acquired the shares in connection with the transaction for investment purposes only the reporting persons believe that the issuer is an attractive investment opportunity depending upon overall market conditions other investment opportunities available to the reporting persons and the availability of shares at prices that would make the purchase or sale of shares desirable the reporting persons may endeavor to increase or decrease their respective positions in the issuer through among other things the purchase or sale of shares on the open market or in private transactions or otherwise on such terms and at such times as the reporting persons may deem advisable no reporting person nor to the best knowledge of the reporting persons without independent verification any other persons named in item  hereof has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs a  j of item  of schedule d except as set forth herein or such as would occur upon completion of any of the actions discussed herein the reporting persons intend to review their respective investments in the issuer on a continuing basis depending on various factors including without limitation the issuers financial position and investment strategy the price levels of the shares conditions in the securities markets and general economic and industry conditions the reporting persons may in the future take such actions with respect to their respective investments in the issuer as they deem appropriate including without limitation communicating with stockholders management and the board of directors of the issuer engaging in discussions with third parties about the issuer and the reporting persons investment making proposals to the issuer concerning changes to the capitalization ownership structure board structure including seeking board representation or operations of the issuer purchasing additional shares selling some or all of their shares engaging in short selling of or any hedging or similar transaction with respect to the shares or changing their intention with respect to any and all matters referred to in item     cusip no      item  interest in securities of the issuer a the aggregate percentage of shares reported owned by each person named herein is based upon  shares of common stock outstanding which is the total of  shares of common stock outstanding as of december   as indicated in the issuers registration statement on form s filed december   the funds svls iv gp and svlsf iv llc may each be deemed to beneficially own in the aggregate  shares of common stock constituting approximately  of the common stock outstanding as of the close of business on the date of this filing svls iv lp owned directly  shares of common stock constituting approximately  of the common stock outstanding as of the close of business on the date of this filing strategic partners owned directly  shares of common stock constituting approximately  of the common stock outstanding svls iv lp and strategic partners each a fund or collectively the funds may be deemed to beneficially own the shares held by each other fund because of certain contractual relationships among the funds and their affiliates the funds disclaim beneficial ownership of shares held by any other fund except to the extent of any pecuniary interest therein svls iv gp the general partner of svls iv lp and strategic partners may be deemed to beneficially own the shares held by svls iv lp and strategic partners svls iv gp disclaims beneficial ownership of shares held by svls iv lp and strategic partners except to the extent of any pecuniary interest therein svlsf iv llc the general partner of svls iv gp may be deemed to beneficially own the shares held by svls iv lp and strategic partners svlsf iv llc disclaims beneficial ownership of shares held by svls iv lp and strategic partners except to the extent of any pecuniary interest therein the investment committee of svlsf iv llc comprised of the members as set forth on schedule a  may be deemed to beneficially own the shares held by the funds as it controls voting and investment decisions over the issuers shares held by the funds by a majority vote each member of the investment committee disclaims beneficial ownership over shares held by the funds except to the extent of any pecuniary interest therein b each of svls iv lp and strategic partners have sole power to vote and dispose of the shares they own directly each of strategic partners svls iv gp and svlsf iv llc may be deemed to have sole power to vote and dispose of the shares reported in this schedule d owned directly by svls iv lp each of svls iv lp svls iv gp and svlsf iv llc may be deemed to have sole power to vote and dispose of the shares reported in this schedule d owned directly by strategic partners voting and investment power over the shares of common stock beneficially owned by the reporting persons has been delegated to svls iv gp svls iv gp has delegated voting and investment decisions to svlsf iv llc which in turn has delegated such decisions to an investment committee comprised of the members as set forth on schedule a  each reporting person and each member of the investment committee disclaims beneficial ownership of the shares except to the extent of any respective pecuniary interest therein as described in item a    cusip no    c item  and item  of this schedule d describe all transactions in the shares of the issuer effected during the past sixty days by the reporting persons and are incorporated herein by reference except as set forth in such items none of the reporting persons nor to the best knowledge of the reporting persons without independent verification any other persons named in item  hereof has effected any transaction in the common stock during the past  days d no person other than the reporting persons is known to have the right to receive or the power to direct the receipt of dividends from or proceeds from the sale of the shares e not applicable   item  contracts arrangements understandings or relationships with respect to securities of the issuer pursuant to rule dk promulgated under the securities exchange act of  as amended the reporting persons have entered into an agreement with respect to the joint filing of this statement and any amendment or amendments thereto item  of this schedule d describes the pretransaction equity owned by the reporting persons and is incorporated herein by reference in connection with the transaction the funds have agreed to enter into lockup agreements each a lockup agreement pursuant to which such persons agreed subject to certain exceptions not to sell transfer or otherwise convey any of the issuers securities held by them for a certain period following the date of the transaction the descriptions contained in this statement on schedule d of the lockup agreement are summaries only and are qualified in their entireties by the actual terms of such agreement which is being filed as exhibit  to this schedule d and is incorporated herein by reference pursuant to rule dk promulgated under the securities exchange act of  as amended the reporting persons have entered into an agreement with respect to the joint filing of this schedule d and any amendment or amendments hereto a copy of which has been filed as exhibit  to this schedule d and is incorporated herein by reference except as set forth herein there are no contracts arrangements understandings or relationships among the reporting persons or between the reporting persons and any other person with respect to the securities of the issuer except as set forth herein to the best knowledge of the reporting persons without independent verification there are no contracts arrangements understandings or relationships among any persons named in item  hereof or between any persons named in item  hereof and any other person with respect to the securities of the issuer   item  material to be filed as exhibits       joint filing agreement by and among sv life sciences fund iv lp sv life sciences fund iv strategic partners lp sv life sciences fund iv gp lp and svlsf iv llc dated february       form of lockup agreement    filed herewith    cusip no    signatures after reasonable inquiry and to the best of his knowledge and belief each of the undersigned certifies that the information set forth in this statement is true complete and correct dated february     svlsf iv llc by   s denise marks name   denise marks title   member sv life sciences fund iv gp lp by svlsf iv llc its general partner by   s denise marks name   denise marks title   member sv life sciences fund iv lp by sv life sciences fund iv gp lp its general partner by svlsf iv llc its general partner by   s denise marks name   denise marks title   member sv life sciences fund iv strategic partners lp by sv life sciences fund iv gp lp its general partner by svlsf iv llc its general partner by   s denise marks name   denise marks title   member    cusip no    schedule a information regarding members of the investment committee of svlsf iv llc   name    residence or business address    present principal occupation or employment principal business of employer    name of employer and address where employment is conducted    citizenship james garvey    co sv life sciences one boston place  washington street suite  boston ma     chairman emeritus international life sciences venture capital investments    sv life sciences one boston place  washington street suite  boston ma     usa kate bingham    co sv life sciences  kingsway london wcb st united kingdom    managing partner international life sciences venture capital investments    sv life sciences  kingsway london wcb st united kingdom    united kingdom eugene hill    co sv life sciences one boston place  washington street suite  boston ma     managing partner international life sciences venture capital investments    sv life sciences one boston place  washington street suite  boston ma     usa david milne    co sv life sciences one boston place  washington street suite  boston ma     managing partner international life sciences venture capital investments    sv life sciences one boston place  washington street suite  boston ma     usa michael ross    co sv life sciences one boston place  washington street suite  boston ma     managing partner international life sciences venture capital investments also a member of the board of directors of catabasis pharmaceuticals inc    sv life sciences one boston place  washington street suite  boston ma     usa cusip no    joint filing agreement in accordance with rule aj and rule dk and under the securities exchange act of  as amended the undersigned agree to the joint filing on behalf of each of them of forms    and schedules d and g including any and all amendments thereto with respect to the common stock par value  per share of ophthotech corporation and further agree that this joint filing agreement shall be included as an exhibit to such joint filings the undersigned further agree that each party hereto is responsible for the timely filing of such forms    and schedules d and lg and any amendments thereto and for the completeness and accuracy of the information concerning such party contained therein  provided  that no party is responsible for the completeness or accuracy of the information concerning any other filing party unless such party knows or has reason to believe that such information is inaccurate this joint filing agreement may be executed in one or more counterparts each of which shall be deemed to be an original instrument but all of such counterparts together shall constitute one agreement in evidence thereof the undersigned being duly authorized hereby execute this joint filing agreement as of february     svlsf iv llc by   s denise marks name   denise marks title   member sv life sciences fund iv gp lp by svlsf iv llc its general partner by   s denise marks name   denise marks title   member sv life sciences fund iv lp by sv life sciences fund iv gp lp its general partner by svlsf iv llc its general partner by   s denise marks name   denise marks title   member sv life sciences fund iv strategic partners lp by sv life sciences fund iv gp lp its general partner by svlsf iv llc its general partner by   s denise marks name   denise marks title   member sv health investors llc top holdings f filings home articles latest filings all funds stocks being bought stocks being sold insider buying free registration required to continue you have viewed  pages within the last  hours to continue please register at holdings channel for unlimited page views and our free weekly newsletter by entering your name and email address below registration is absolutely free by registering you agree to our privacy policy  terms of use if you are in canada you must click here for alternate registration page problems with your registration sticking enable your browser to receive our cookie to resolve other questions email us at infoholdingschannelcom sv health investors llc top holdings f filings  wwwholdingschannelcom  copyright     all rights reserved nothing in holdings channel is intended to be investment advice nor does it represent the opinion of counsel from or recommendations by bnk invest inc or any of its affiliates subsidiaries or partners none of the information contained herein constitutes a recommendation that any particular security portfolio transaction or investment strategy is suitable for any specific person all viewers agree that under no circumstances will bnk invest inc its subsidiaries partners officers employees affiliates or agents be held liable for any loss or damage caused by your reliance on information obtained by visiting using or viewing this site you agree to the following full disclaimer  terms of use and privacy policy video widget and market videos powered by market news video quote and option data delayed at least  minutes stock quote data powered by ticker technologies and mergent contact holdings channel meet our editorial staff svlsf iv llc  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors svlsf iv llc check out list of companies and businesses related to svlsf iv llc find out svlsf iv llc address and contact details view other people related to svlsf iv llc  coworkers colleagues companions etc address  state street suite  boston  ma companies related to svlsf iv llc cikcompany namepositioncompany addresskalvista pharmaceuticals inc owner one kendall square building  ste  cambridge entellus medical inc owner  holly lane north suite  plymouth neurogesx inc owner  bridgepointe parkway suite  san mateo ocular therapeutix inc owner  crosby drive bedford  svlsf iv llc on the web persons related to svlsf iv llc  kalvista pharmaceuticals incnamepositioncityacmp iv llc owner san franciscoacp iv lpsan franciscocha albertpalo altocha albertpalo altorichard aldrichdirector bostonsteven l bastadirector san mateoalbert chadirector danburyehrlich chrispalo altodavid m clapperdirector menlo parkbruce a clevelandsan mateothomas andrew crockettceo salisbury wiltshireclapper davidpalo altogravett davidpalo altogravett davidpalo altorenzi davidpalo altounkart edwardpalo altoedward p feenerchief scientific officer salisbury wiltshiredaniloff georgepalo altophilip t gianosdavid m gravettvp research  development palo altonohra guypalo altonohra guypalo altolewis hayleypalo altow stephen holmesmenlo parkinterwest management partners ix llc owner menlo parkinterwest partners ix lpmenlo parkdaniel janneysan franciscokeith katkindirector san diegokatkin keithpalo altonina s kjellsonmenlo parkgilbert h klimanmenlo parkpeter kolchinskybostonhayley lewissee remarks palo altoandreas maetzelsenior vice president medical carymaroney marceepalo altomaroney marceepalo altoweeks markpalo altomarcee maroneyvp clinical affairs palo altojohn mckunesee remarks palo altokhaled nasrsan franciscoguy p nohradirector san franciscoas novobagsvaerdarnold l oronskydirector menlo parkben palleikocfo and secretary danburydouglas a peppermenlo parkra capital biotech fund lpbostonra capital management llcdirector bostonpremchandran ramiyavice president of supply chain palo altodavid renzipresident  ceo palo altojoshua resnickdirector bostonzadno rezapalo altodubois roxannepalo altodavid joseph sauldirector palo altorajeev m shahdirector bostonbasta stevenpalo altobasta stevenpalo altosv life sciences fund iv gp lpbostonsv life sciences fund iv lpbostonsv life sciences fund iv strategic partners l pbostonwhite tpalo altotrapp timothypalo altoedward w unkartdirector san josevivo ventures fund vi lppalo altovivo ventures vi affiilates fund lppalo altovivo ventures vi llc owner palo altothomas michael whitepalo altochristopher yeachief development officer salisbury wiltshirereza zadnodirector palo altopersons related to svlsf iv llc  entellus medical incnamepositioncityjohn k bakewelldirector arlingtonjoshua j baltzelldirector walthamjoshua j baltzellplymouthmargaret a boianovp healthcare policyreimburse plymouthmoen brentplymouthfarley brianmaple grovefarley brianplymouthfarley brianlos altosjonelle r burnhamvice president  genl counsel st paulmartha j christianvice president reimbursement plymouthmilne davidplymouthmilne davidbostonmilne davidbostongonzales donaldplymouthrohlen douglasplymouthessex woodlands health ventures fund viiia lpthe woodlandsessex woodlands health ventures fund viiia lpthe woodlandsessex woodlands health ventures fund viiib lpthe woodlandsessex woodlands health ventures fund viiib lpthe woodlandsessex woodlands health ventures fund viii lpthe woodlandsessex woodlands health ventures fund viii lpthe woodlandsessex woodlands health ventures viii llc owner the woodlandsessex woodlands health ventures viii lpthe woodlandsbrian e farleydirector san josebrian e farleyplymouthdonald a gonzalesplymouththomas e griffinchief financial officer plymouthneels guidopalo altoneels guidopalo altoneels guidoplymouthilsf iii llcbostoninternational life sciences fund iii coinvestment lpbostoninternational life sciences fund iii gp lpbostoninternational life sciences fund iii lp lpbostoninternational life sciences fund iii strategic partners lpbostonmomtazee jamesplymouthbakewell johnplymouthburnham jonelleplymouthbaltzell joshuaeden prairiebaltzell joshuaplymouthpeterson karenplymouthmensink kevinplymouthjeff l koglvp bus dev  strategy plymouthchristian marthaplymouthshawn mccormickdirector plymouthshawn mccormickdirector plymouthkevin l mensinkvice president marketing plymouthrosenthal michaelplymouthdavid bruce milnedirector bostondavid bruce milneplymouthbrent moencfo and secretary minneapolisjames c momtazeedirector anaheimguido j neelsdirector indianapolisguido j neelsdirector plymouthstephen r paidoshvice president operations plymouthkeith petermaple grovekaren e petersonvp regulatory  quality plymouthtimothy b petrickvp research  development plymouthwhite robertplymouthduke rohlendirector redwood citymichael harry rosenthalplymouthmccormick shawnplymouthsplit rock partners lp owner eden prairiesplit rock partners management llceden prairiepaidosh stephenplymouthjames d surekvice president sales plymouthsv life sciences fund iv gp lpbostonsv life sciences fund iv lpbostonsv life sciences fund iv lpbostonsv life sciences fund iv strategic partners l pbostonsv life sciences fund iv strategic partners l pbostongriffin thomasmaple grovewilliamson thomasplymouthressemann thomasmaple grovepetrick timothyplymouthrobert s whitepresident and ceo plymouthrobert s whitepresident  coo plymouththomas p williamsonvice president sales plymouthpersons related to svlsf iv llc  neurogesx incnamepositioncityalta biopharma management iii llc owner san franciscoalta biopharma management iii llcsan franciscoalta biopharma partners iii gmbh  co beteiligungs kgsan franciscoalta biopharma partners iii lpsan franciscoalta california management partners ii llcsan franciscoalta california management partners ii llc  new poolsan franciscoalta california partners ii lp  new poolsan franciscoalta california partners ii lpsan franciscoalta embarcadero biopharma partners iii llcsan franciscoalta embarcadero partners ii llcsan franciscoditonno anthonysan mateoditonno anthonysan mateoarch v entrepreneurs fund lpchicagoarch venture fund v lp owner chicagoarch venture partners v llcchicagoarch venture partners v lp owner chicagomoshe arkin owner herzeliamoshe arkin owner herzeliaasian venture capital investment corpsan franciscojean jacques bienaimedirector san carlosjean jacques bienaimesan carlosjean jacques bienaimedirector san carloskeith r bleysvp nonclinical r  d san carloskeith r bleysvp nonclinical r  d san mateokeith r bleysvp nonclinical r  d san mateogoodwin bradfordsan mateogoodwin bradfordsan mateodoron breen tel avivdoron breen tel avivdoron breentel avivclinton bybeechicagofarah champsisan franciscomanish chapekarmenlo parkmary colemanpalo altokeith crandellchicagodeerfield capital lpnew yorkmanagement co ny deerfieldnew yorkdeerfield special situations fund international ltdroad town tortoladeerfield special situations fund lpnew yorkjean deleagesan franciscoanthony a ditonnosan carlosanthony a ditonnopresident ceo and director san mateoanthony a ditonnopresident  ceo san mateojames e flynn owner new yorklyons garysan mateolyons garysan mateostephen f ghiglierisan carlosstephen f ghiglierichief financial officer san mateostephen f ghiglieriexec vp coo  cfo san mateostephen f ghiglieriexec vp coo  cfo san mateobradford s goodwindirector san mateobradford s goodwindirector san mateogarrett gruenersan franciscokaren j hardersvp reg affairs san carloskaren j hardersvp reg affairs san mateohealthcare focus fund lpchicagoedward hurwitzsan franciscointernational venture capital investment corpsan franciscointernational venture capital investment iii corpsan franciscoivcicwalden management co ltdsan franciscodaniel janneysan franciscobienaime jeanjacquessan mateotobias jeffreysan mateoorwin johnsan mateoorwin johnsan mateoandrew kausan franciscorussell t kawahatav p pharmaceutical science san mateorussell t kawahatavp pharmaceutical science san mateoneil m kurtzsan carlosneil m kurtzsan carlosneil m kurtzdirector san mateoneil m kurtzdirector san mateosteven lazaruschicagohock voon loosan franciscogary a lyonsdirector san mateogary a lyonsdirector san mateom arkin  ltdherzliam arkin  ltdherzeliam arkin  ltdherzeliaalix mardueldirector san franciscomichael markelssan carlosmichael markelsvp commercial ops and bus dev san mateomichael markelssenior vpcommercial  bus dev san mateomichael markelssenior vp comm and bus dev san mateomichael markelssenior vpcommercial  bus dev san mateoron martellpresident and ceo san mateoron martellpresident and ceo san mateomarkels michaelsan mateomontreux equity management ii sbic llcmenlo parkequity managment sbic montreux iiimenlo parkmontreux equity partners ii sbic lpmenlo parkisrael mortel avivisrael mortel avivkurtz neilsan mateokurtz neilsan mateorobert nelsenchicagorobert nelsendirector chicagorobert nelsendirector san mateorobert nelsendirector chicagorobert nelsendirector chicagorobert nelsenchicagosteven h nelsondirector san mateoguy p nohrasan franciscojohn a orwindirector san mateopacven walden management v co ltdsan franciscowalden ventures parallel va cv pacvensan franciscowalden ventures parallel vb cv pacvensan franciscopacven walden ventures v associates fund lppacven walden ventures v lppacven walden ventures v qp associates fund lphoward d palefskymenlo parkbruce peacockdirector san mateobruce peacockdirector san carlosbruce peacockdirector san mateoedward penhoetsan franciscostephen j peroutkasan mateostephen j peroutkavice president and cmo san mateostephen j peroutkavice president and cmo san mateosusan p rinnesan mateosusan p rinnevp regulatory affairs san mateosusan p rinnevice president regulatory san mateonelsen robertsan mateonelsen robertsan mateomartell ronaldsan mateomartell ronaldsan mateojohn savaresemenlo parkseed ventures iii pte ltdsan franciscoron senatortel avivron senatortel avivron senatortel avivsphera funds management ltdtel avivghiglieri stephensan mateoghiglieri stephensan mateoghiglieri stephensan mateoperoutka stephensan mateoperoutka stephensan mateonelson stevensan mateonelson stevensan mateonelson stevensan mateosv life sciences fund iv gp lpbostonsv life sciences fund iv gp lpbostonsv life sciences fund iv lpbostonsv life sciences fund iv lpbostonsv life sciences fund iv strategic partners l pbostonsv life sciences fund iv strategic partners l pbostonlip bu tansan franciscojeffrey k tobiassan carlosjeffrey k tobiaschief medical officer san mateojeffrey k tobiascmo evp research  deve san mateodaniel k turner iiimenlo parkdaniel k turner iiimenlo parkdaniel k turner iiidirector menlo parkdaniel k turner iiimenlo parkwalden international singapore pte ltdsan franciscopersons related to svlsf iv llc  ocular therapeutix incnamepositioncitycrain alanwalthamcrain alanwalthamcrane alanbedfordsawhney amarpreetwalthamsawhney amarpreetbedforderic ankerudsee remarks bedfordascension health ventures ii llcclaytonhaffey bernardwalthamlevy brianwalthamjaswinder chadhadirector bedfordwarden charleswalthamwarden charlesbedfordchv ii lp owner claytonalan l cranewalthammyers danielbedfordkhosravi farhadwalthamkhosravi farhadbedfordjames fortunechief operating officer bedfordjames m garveydirector houstonjames m garveybostonjeffrey s heierdirector bedfordcharles andrew hurleychief commercial officer bedfordgarvey jamesbedfordrichard l md lindstromdirector wayzatarichard l md lindstromdirector bedfordantony c mattessichdirector bedfordgeorge v migauskygaithersburgwilliam j osheadirector bruce peacockdirector bruce peacockbedfordbruce peacockdirector bedfordpolaris venture management co v llc owner walthampolaris venture partners entrepreneurs fund v lpwalthampolaris venture partners founders fund v lpwalthampolaris venture partners special founders fund v lpwalthampolaris venture partners v lpwalthamlindstrom richardwalthamwu samuelwalthamamarpreet sawhneypresident and ceo bedfordw bradford smithcfo and treasurer walthamw bradford smithcfo and treasurer bedfordcagnetta stevenwalthamsv life sciences fund iv gp lpbostonsv life sciences fund iv gp lpbostonsv life sciences fund iv lpbostonsv life sciences fund iv lpbostonsv life sciences fund iv strategic partners l pbostonsv life sciences fund iv strategic partners l pbostonjonathan h talamochief medical officer bedfordversant side fund iii lpmenlo parkversant side fund iii lpmenlo parkversant venture capital iii lp owner menlo parkversant venture capital iii lpmenlo parkcharles m wardendirector menlo parkcharles m wardendirector bedford potentially same personnamecitycountrysvlsf iv llcbostonmasvlsf iv llcbostonmasvlsf iv llcbostonma  svlsf ivc llcs insider stock buys and sells home homepage membership levels membership data coverage complete stock list founders message the book free trial screeners value screens allinone screener industry overview ben graham netnet undervalued predictable buffettmunger screener magic formula greenblatt historical low ps list historical low pb list peter lynch screen high short interest weekyy lows weekyy highs predictable companies sp  grid dividend stocks spin off list downloads  tools excel addin guruf manual of stocks™ download financial data download guru portfolios download stock pdfs download insider data api mobile app strategies performances buffettmunger undervalued predictable low ps low pb broadest owned most weighted gurus latest guru picks real time picks list of gurus personalize gurus portfolios scoreboard top  holdings view sector picks international picks aggregated portfolio consensus picks guru bargains hot picks industry trends geographic trend etfs options european shorting insiders all insiders ceo buyssales cfo buyssales insider cluster guruinsider double buys triple buyssales insider trends canadian insider dutch insider market market valuation economic data industry overview marketcapgdp valuation global market valuation shiller pe shiller pe by sectors buffett assets allocation by country usa australia canada china germany india japan uk more articles articles editors picks gurufocus research value ideas interviews with gurus top ranked value idea contest videos following authors submit articles writers wanted value contest winners submit articles online my articles conference value conference speakers locationvenue register after conference gathering free drinks tutorials tutorials  webinars faq contact us log in free signup log in day free trial subscribe free trial year refer a friend  earn  search compare search ▾ get day free trial my portfolios▾ portfolios overview create new portfolio portfolio contest my gurus▾ quick browse personalize my gurus premium gurus premium plus investors summarycanadian dutch ceo buys cfo buys insider cluster buys double buys triple buys data export trend saved usa canada ukireland europe asia oceania latin america africa currently selected show all countries ▾ purchase to select this region purchase  usa otcpk nas nyse arca otcbb amex bats purchase to select this region purchase  canada tsxv tsx xcnq purchase to select this region purchase  ukireland uk purchase to select this region purchase  europe germany france poland russia sweden turkey bosnia and herzegovina italy luxembourg switzerland belgium greece norway spain denmark bulgaria netherlands romania finland serbia austria croatia portugal slovakia cyprus macedonia slovenia ukraine hungary lithuania latvia malta iceland estonia czech republic all countries ▾ purchase to select this region purchase  asia india japan korea thailand hongkong china taiwan malaysia singapore israel indonesia pakistan vietnam philippines sri lanka kuwait nepal saudi jordan oman iran iraq united arab emirates kazakhstan bahrain all countries ▾ purchase to select this region purchase  oceania australia new zealand purchase to select this region purchase  latin america brazil mexico argentina chile peru columbia jamaica venezuela ecuador purchase to select this region purchase  africa south africa egypt nigeria mauritius morocco zimbabwe kenya tunisia ghana côte divoire set as default insider trades try insider screener  svlsf ivc llcs insider stock buys and sellsto find out why gurufocus thinks data on insider trades is interesting read can aggregated insider trading activities predict the market stocks that both gurus and insiders are buying can aggregated insider trading activities predict the market of different sectors filter by   default search insider trade go select to drill down all market capmicro cap small cap mid cap large cap mega cap sp  companies all sectorsbasic materials consumer cyclical financial services real estate consumer defensive healthcare utilities communication services energy industrials technology display those with at least          shares display stocks that are within please select        of please select week lowyear lowyear lowreal time insider typebuysellinsider sentiment chart recent filings activity no insider trades foundtotal records  per page ▾     add this list into my watchlistportfolio  add or remove tickers comma separated up to  symbols  select destination portfolioyou need to log in to proceed  click the button to finish only the transactions in open market or private sale at the market prices are included other transactions such as conversion of derivative security or exercise of options are not included insiders are limited to only officers andor directors of the company select portfolios create a new portfolio why you are interested your selection and notes will be stored in your portfolio login to add portfolio get wordpress plugins for easy affiliate links on stock tickers and guru names  earn affiliate commissions by embedding gurufocus charts gurufocus affiliate program earn up to  per referral  learn more home  about   jobs   advertise    site map    term of use    privacy policy     rss    mobile app     email alerts    referral program    affiliate program    faq    contact us      gurufocuscom llc all rights reserved disclaimers gurufocuscom is not operated by a broker a dealer or a registered investment adviser under no circumstances does any information posted on gurufocuscom represent a recommendation to buy or sell a security the information on this site and in its related newsletters is not intended to be nor does it constitute investment advice or recommendations the gurus may buy and sell securities before and after any particular article and report and information herein is published with respect to the securities discussed in any article and report posted herein in no event shall gurufocuscom be liable to any member guest or third party for any damages of any kind arising out of the use of any content or other material published or available on gurufocuscom or relating to the use of or inability to use gurufocuscom or any content including without limitation any investment losses lost profits lost opportunity special incidental indirect consequential or punitive damages past performance is a poor indicator of future performance the information on this site and in its related newsletters is not intended to be nor does it constitute investment advice or recommendations the information on this site is in no way guaranteed for completeness accuracy or in any other way the gurus listed in this website are not affiliated with gurufocuscom llc stock quotes provided by interactive data fundamental company data provided by morningstar updated daily gf chat  × manage bookmarks close feedback svlsf iv llc top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active svlsf iv llc • boston ma how do i update this listing svlsf iv is based out of boston whalewisdom has at least  dg filings in our database for svlsf iv summary dg insider form  uk holdings create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from svlsf iv llc enter your email address below and choose submit your email cancel contact info svlsf iv llc one boston place boston ma     business phone  recent sec filings fnt filed on  sc da filed on  sc ga filed on  sc ga filed on  sc ga filed on  sc d filed on  fnt filed on   filed on  sc da filed on   filed on  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading experimental current uk positions updated daily contains transactions from january st  on holder issuer transaction date number of voting rights  of voting rights svlsf iv llc reneuron group    position history holder issuer transaction date number of voting rights  of voting rights elevate your investments try it for free kalvista pharmaceuticals inc nasdaqkalv is attracting money  small cap exclusive kalvista pharmaceuticals inc nasdaqkalv is attracting moneyhomebiotech healthcare newskalvista pharmaceuticals inc nasdaqkalv is attracting money kalvista pharmaceuticals inc nasdaqkalv is attracting money march      richard schwarz  biotech  in a just published form  filed with the us securities and exchange commission sec kalvista pharmaceuticals inc nasdaqkalv reported that svlsf iv llc has picked up   of common stock as of the acquisition brings the aggregate amount owned by svlsf iv llc to a total of  representing a  stake in the companyfor those not familiar with the company kalvista pharmaceuticals inc formerly carbylan therapeutics inc is a clinicalstage pharmaceutical company the company is focused on the discovery development and commercialization of small molecule protease inhibitors for a range of diseases the company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema hae and diabetic macular edema dme the company is developing a plasma kallikrein inhibitor which is administered directly into the eye the company is engaged in advancing several product candidates developed from its portfolio into early clinical trials the company is progressing additional oral candidates towards regulatory preclinical studies the company’s hae product candidate kvd is an inhibitor of plasma kallikrein the company has initiated clinical testing of kvd in a phase i clinical trial it has completed an openlabel single ascending dose phase i trial in dme patients with kvda glance at kalvista pharmaceuticals inc nasdaqkalv’s key stats reveals a current market capitalization of  million based on  million shares outstanding and a price at last close of  per sharelooking at insider activity there are a few transactions worth notingspecifically on  cha picked up  at a purchase price of  this brings their total holding to  as of the date of the filingon the sell side the most recent transaction saw renzi unload  shares at a sale price of  this brings their total holding to it’s possible to gauge a company’s potential by tracking the activity of its major holders as well as checking in on insider activity such as those transactions listed above we’ll be keeping an eye on kalvista pharmaceuticals inc nasdaqkalv as things move forward to see if its progress aligns with these transactionssubscribe below and we’ll keep you on top of what’s happening before it moves markets   tags healthcare nasdaqkalv pharmaceuticals share  richard schwarz richard schwarz is a veteran analyst in the small cap space with a particular focus on the development stage biotech sector he is a native of canada and attended nyu before working for a host of big name pharma outfitsrelated post vaccination diabetes and a company working to bring the space up to date may    three companies that could change the face of healthcare ilmn vbiv jnj may    guess who picked onconova therapeutics inc nasdaqontx shares may    arena pharmaceuticals inc nasdaqarna is attracting smart money april    leave a reply cancel replyyour email address will not be published required fields are marked commentname  email  website top brokers review trade now reviewtrade now reviewtrade nowpromotioncopyright   all rights reservedtopenter your name and email and get the weekly newsletter its freeintroduce yourself and your programyour information will never be shared or sold to a rd party